FDA OKs New Therapy for Some Hemophilia Patients - NBC Connecticut
National & International News
The day’s top national and international news

FDA OKs New Therapy for Some Hemophilia Patients

Genentech, the drug's developer, says the list price will be about $482,000 for the first year and slightly less after that

    processing...

    NEWSLETTERS

    How Doctors are Shining New Light on Skin Cancer Diagnoses
    AP/Genentech, Inc.
    This photo provided by Genentech, Inc. shows a package of the drug Hemlibra. On Thursday, Nov. 16, 2017, the Food and Drug Administration approved Hemlibra, the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

    U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

    The Food and Drug Administration on Thursday approved Hemlibra (hem-LEE'-bruh), a weekly injection for hemophilia A patients who have developed resistance to standard medicines.

    Genentech, the drug's developer, says the list price will be about $482,000 for the first year and slightly less after that.

    Genentech, a subsidiary of Swiss drugmaker Roche, says that's half the cost of the only other option for patients with this resistance. That treatment requires an IV drip several times a week.

    WH: Cannot Guarantee Trump Didn't Use N-Word

    [NATL] WH Defends Trump's 'Dog' Comment, Says They Cannot Guarantee Trump Didn't Use N-Word

    The White House defended President Donald Trump calling former protégée Omarosa Manigault-Newman a "dog" in a Tuesday press conference. Press secretary Sarah Huckabee Sanders also could not guarantee that Trump has never used the N-word on record, but doubled down in his defense. 

    (Published Tuesday, Aug. 14, 2018)

    Hemophilia mostly affects males.